Liu Juan, Yin Jia
Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, Beijing, China.
National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China.
Front Allergy. 2024 Aug 22;5:1453446. doi: 10.3389/falgy.2024.1453446. eCollection 2024.
The clinical efficacy of allergen-specific immunotherapy (AIT) for () and () extracts remains largely unknown in China. We sought to retrospectively evaluate the efficacy caused by AIT agents manufactured in China of patients who are sensitized to and .
Patients aged 5-27 years with asthma and perennial allergic rhinitis (AR), and AIT with and were recruited, and then classified into two groups: -AIT ( = 31) and + -AIT group ( = 39). All data were gathered retrospectively, including biological parameters, pulmonary function, and symptom and medication scores.
70 patients who underwent and AIT were enrolled. A significant improvement was observed in the values of FEV1% ( < 0.0001) and MEF 25 ( = 0.023) of lung function. Both the rhinitis symptoms and combined symptoms and medication scores for asthma decreased after AIT (by 45.3% and 80.3%, respectively, < 0.0001 for each). Nearly 67% improvement rate ( < 0.0001) occurred in rhinoconjunctivitis quality of life, and a great increase existed in Asthma Control Test (ACT) score ( < 0.0001) after at least 1 year AIT, although there were no significant changes between these two groups. Besides, no significance was displayed in specific IgE to different allergens.
AIT with and extracts had clinical efficacy for many patients in China, with a reduction of symptom and medication scores, and great improvement in spirometry function.
在中国，针对（）和（）提取物的变应原特异性免疫疗法（AIT）的临床疗效在很大程度上尚不清楚。我们试图回顾性评估中国生产的AIT制剂对致敏于（）和（）的患者的疗效。
招募年龄在5至27岁之间患有哮喘和常年性变应性鼻炎（AR）且接受（）和（）AIT治疗的患者，然后将其分为两组：-AIT组（n = 31）和+ -AIT组（n = 39）。所有数据均为回顾性收集，包括生物学参数、肺功能以及症状和用药评分。
70例接受（）和（）AIT治疗的患者入组。观察到肺功能的FEV1%值（P < 0.0001）和MEF 25（P = 0.023）有显著改善。AIT治疗后，鼻炎症状以及哮喘的综合症状和用药评分均下降（分别下降45.3%和80.3%，每项P < 0.0001）。在至少1年的AIT治疗后，鼻结膜炎生活质量改善率近67%（P < 0.0001），哮喘控制测试（ACT）评分大幅提高（P < 0.0001），尽管两组之间无显著变化。此外，对不同变应原的特异性IgE无显著差异。
在中国，使用（）和（）提取物进行AIT治疗对许多患者具有临床疗效，可降低症状和用药评分，并显著改善肺量计功能。
